Background: Viral hepatitis C (HCV) is common in Benin. Untreated, it can be complicated by cirrhosis and hepatocarcinoma, which are sources of death. The objectives of this work were twofold: 1) to evaluate the effectiveness and safety of treatment with classic dual interferon pegylated alpha-2a (IFN) and ribavirin therapy in Benin, and 2) to present problems related to financial accessibility to this treatment. Methods: This was a cross-sectional, descriptive and analytical study, with a retrospective collection of data from November 1, 2010 to December 31, 2015 and prospective collection from January 1, 2016 to July 31, 2016 (7 months). We included all patients treated with IFN + ribavirin for hepatitis C at CNHU/HKM. Sustained virological response (SVR) was defined as undetectable viral load C 6 months after stopping treatment. Safety was appreciated by the search for clinical and hematological adverse effects. Results: One hundred and six patients were followed for HCV, of whom 58 (54.7%) undergoing treatment (26 under standard dual therapy and 32 under direct-acting antivirals). Of the 26 patients underconventional dual therapy, 12 (46.1%) were genotype 1, 13 (50%) genotype 2 and one (3.9%) genotype 4. In conventional dual therapy, SVR was achieved in 15 (57.7%) patients, including the genotype 4 patient, 4 out of 12 (33.3%) genotype 1 patients, and 10 out of 13 (76.9%) for genotype 2 patients. The most common side effects with this treatment were severe asthenia (23 cases), flu-like symptoms (22 cases), weight loss (21 cases) and neutropenia (22 cases), anemia and thrombocytopenia (20 of 26 cases). The overall cost of treatment per patient was 11,800,624 FCFA for genotypes 1 and 4; and 
Introduction
Viral hepatitis is defined as any diffuse inflammatory process of the liver due to viruses with dominant hepatic tropism [1] . There are five types of viruses: A, B, C, D and E. But only some of them can cause chronic hepatitis. These are mainly hepatitis B and C viruses that will therefore be the subject of therapeutic drug management. Hepatitis E virus can also give chronic forms but only in immunocompromised individuals.
The World Health Organization (WHO) estimated in 2015 to 71 million, the number of chronic carriers of the hepatitis C virus (HCV) worldwide [2] . Nearly 63% of those infected before the age of 40 progress to chronic infection with a 5% incidence of cirrhosis in 20 years and an annual mortality from chronic liver failure of 3.7% after the onset of cirrhosis [3] [4] . HCV infection is a major public health problem in developing countries. WHO estimates that in some countries, such as Egypt and Cameroon, its prevalence would be 10% to 15%. In Benin, it is estimated at 4.12% in blood donors [5] . The chronic forms of hepatitis B and C are most often the cause of death by their complications which are cirrhosis and hepatocellular carcinoma. But, effective treatments are available to avoid the occurrence of these complications and to obtain healing.
Although treatment for viral hepatitis C (VHC) has been around for many years and is widely used in developed countries, the high cost of pharmaceuticals (pegylated interferon and ribavirin) and pre-, per-, and post-treatment assessment has long been a brake on its implementation in developing countries, including Benin. Since 2010, a subsidy granted by the State allowed to begin in Benin a therapeutic management of the VHC. Two treatment regimens are available: traditional dual therapy (interferon + ribavirin) used since 2010 and direct-acting antivirals (DAAs) since the end of 2015.
No previous study has addressed the treatment of hepatitis C in Benin. The objectives of this study were to evaluate the effectiveness of the treatment by conventional dual therapy of patients with VHC in Benin as well as the tolerance and the cost of this treatment. recruitment was carried out in all the patients followed in the department for chronic hepatitis C during the period and placed on conventional dual therapy.
The conventional dual therapy included pegylated interferon alpha-2a 180 μg/week subcutaneously plus ribavirin 800 to 1200 mg/day per os. Patient consent was obtained prior to inclusion in the study. Among them, were selected those in whom a therapeutic response was evaluable (treatment completed with a viral load carried out 6 months after the end of treatment). Sustained viral response (SVR) was defined as undetectable viral load C 6 months after the end 
Results

Characteristic of the Studied Population
A total of 1,764 patients had been received for consultation in the department during the study period. Among them, 106 patients (6%) had hepatitis C, 
Effectiveness of Treatment
Tolerance of Treatment
The Treatment was discontinued due to severe anemia, thrombocytopenia and neutropenia side effects in 3 genotype 1 and 2 genotype 2 patients.
The management of adverse events occurring with interferon + ribavirin 
Cost of Treatment
The cost of the pre-therapeutic assessment in the patients to be treated was 
Discussion
The percentage of patients treated was 54.7%. This rate is relatively low as it is currently recommended to treat all patients with chronic hepatitis C [6] [7] . This low rate is due to the fact that only patients with at least moderate fibrosis (F > 1) were selected for treatment. This limitation of access to treatment is explained by a prioritization for economic reasons. In terms of treatment efficacy, in our study, the overall SVR was 57.7%. This result is similar to the 56% reported in a multicentric study by Fried MW et al. [8] . [15] . In studies in America and Western Europe, the SVR for genotype 2 was 80% [10] . According to studies by Fried MW et al. [8] , Hadziyannis SJ et al. [9] and Manns M et al. [11] , it was 76% for naïve patients of genotype 2. The value found in our study is lower than the 100% mentioned by Farley JD et al. [13] . It is also higher than those of 58.8% and 60% respectively found by Maru et al. [12] and Chew et al. [14] . For genotype 4, we had only one genotype 4 patient treated with pegylated interferon + ribavirin for 48 weeks in whom SVR was obtained.
Concerning the predictive factors of response under the classic bitherapy, those especially mentioned are the genotype and the existence or not of a The main limitation of this work is the small number of patients treated with the conventional dual therapy, explaining the low power of the study.
Conclusion
The treatment of HCV with IFN + ribavirin in Benin is effective especially for genotype 2. But its adverse effects are manifold and its cost is high. The switch to direct-acting antivirals (more effective, better tolerated and less expensive) was
